1. New interim data on RGX-202 will be presented at MDA Conference. 2. Data could influence RGNX's stock perception ahead of clinical trial outcomes. 3. Presented by a Clinical Professor at Stanford, ensuring credibility. 4. Upcoming presentation scheduled for March 19, 2025, at 8:15 a.m. CT. 5. RGN continues advancing its AAV Therapeutics pipeline for rare diseases.
Positive clinical data typically leads to increased investor confidence. Historical instances show stock appreciation following favorable trial results.
The presentation of clinical data can significantly impact stock price due to investor sentiment. Most investors respond favorably to promising data from clinical trials.
Event scheduled for March 2025 may drive immediate investor interest. Short-term price movements often follow clinical data releases.
Session: Clinical Trials
Date/Time: Wednesday, March 19, 2025; 8:15 a.m. CT
Presenter: Carolina Tesi Rocha, M.D., Clinical Professor, Neurology, Stanford School of Medicine, Stanford Children's Health
Session: Pre-Clinical Research
Presenter: Steven Foltz, Ph.D., Senior Scientist, Research & Early Development at REGENXBIO
The presentations will be available in the Publications section of REGENXBIO's website.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for rare and retinal diseases, including RGX-202 for the treatment of Duchenne, ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' Zolgensma® for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.
Dana Cormack
Corporate Communications
Email: [email protected]
Investors:
George E. MacDougall
Investor Relations
Email: [email protected]
SOURCE REGENXBIO Inc.